HIGH DOSE SUPPLEMENTS TO REDUCE HOMOCYSTEINE AND SLOW THE RATE OF COGNITIVE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 具体目标： 主要： 1.确定大剂量叶酸/B6/B12补充剂降低同型半胱氨酸水平是否会减缓AD患者的认知衰退速度 次要： 2.确定大剂量叶酸/B6/B12补充剂降低同型半胱氨酸水平是否会减缓AD患者的临床下降率，这是通过达到临床显著终点的时间来衡量的 3.确定大剂量叶酸/B6/B12补充剂降低同型半胱氨酸水平是否会有利地影响AD患者的行为、日常生活能力、全球地位和生活质量 4.检测载脂蛋白E和亚甲基四氢叶酸还原酶(MTHFR)基因对AD患者同型半胱氨酸还原的影响 5.确定大剂量补充剂长期治疗AD患者的安全性和耐受性

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: Primary: 1. Determine whether reduction of homocysteine levels with high-dose folic acid/B6/B12 supplementation will slow the rate of cognitive decline in subjects with AD Secondary: 2. Determine whether reduction of homocysteine levels with high-dose folic acid/B6/B12 supplementation will slow the rate of clinical decline, as measured by the time to reach clinically significant end-points, in subjects with AD 3. Determine whether reduction of homocysteine levels with high-dose folic acid/B6/B12 supplementation will favorably influence measures of behavior, activities of daily living, global status, and quality of life in subjects with AD 4. Examine the influence of apolipoprotein E and methylenetetrahydrofolate reductase (MTHFR) genotype on homocysteine reduction in subjects with AD 5. Determine the safety and tolerability of long-term treatment of AD subjects with high-dose supplements